• Profile
Close

Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The amaranth and daybreak-ALZ randomized clinical trials

JAMA Feb 19, 2020

Wessels AM, Tariot PN, Zimmer JA, et al. - Researchers investigated whether lanabecestat slows the progression of Alzheimer disease (AD) compared with placebo in patients with early AD (mild cognitive impairment) and mild AD dementia. They performed two multicenter, global, double-blind studies at 257 and 251 centers in 15 and 18 countries or territories, respectively. AMARANTH included 2,218 randomized participants, of whom 539 individuals completed the study. DAYBREAK-ALZ included 1,722 (30.2%) randomized participants, of whom 76 individuals completed the study. In all, the researchers found that although lanabecestat was generally well tolerated, it did not slow cognitive or functional decline in individuals with early or mild AD dementia.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay